EMA Withdrawn: Clopidogrel DURA (clopidogrel (as hydrochloride)) — Mylan dura GmbH

View source ↗

Summary

The EMA has withdrawn Clopidogrel DURA (clopidogrel hydrochloride) from the market for peripheral vascular diseases, stroke, and myocardial infarction indicatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction
• Peripheral Vascular Diseases
• Stroke

Drugs mentioned

• Clopidogrel DURA (clopidogrel (as hydrochloride))

Snippet

Status: Withdrawn. Therapeutic area: Peripheral Vascular Diseases;Stroke;Myocardial Infarction. MAH: Mylan dura GmbH. Decision date: 05/05/2015